1. Chirila F, Khan T, Alkon D. Spatiotemporal Complexity of Fibroblast Networks Screens for Alzheimer’s Disease. Journal of Alzheimer’s Disease 2013;33:165-76.
  2. Chirila F, Khan T, Alkon D. Fibroblast Aggregation Rate Converges with Validated Peripheral Biomarkers for Alzheimer’s Disease. Journal of Alzheimer’s Disease. 201;42:1279-91.
  3. Etcheberrigaray R, Ito E, Kim C, Alkon D. Soluble p-Amyloid Induction of Alzheimer’s Disease Phenotype for Human Fibroblast K+ Channels, Science. 1994;264:276-9.
  4. Khan T, Alkon D. An internally controlled peripheral biomarker for Alzheimer’s Disease: Erk1 and Erk2 responses to the inflammatory signal bradykinin. PNAS. 2006;103(35):13203-7.
  5. Khan T, Nelson T, Verma V, Wender P, Alkon D. A cellular model of Alzheimer’s Disease therapeutic efficacy: PKC activation reverses Ap-induced biomarker abnormality on cultured fibroblasts. Neurobiology of Disease. 2009;34:332-9.
  6. Khan T, Alkon D. Early diagnostic accuracy and pathophysiologic relevance of an autopsy confirmed Alzheimer’s Disease peripheral biomarker. Neurobiology of Aging. 2010;31:889-900 (available online 2008).
  7. Khan T. Sen A, Hongpaisan J, Lim C, Nelson T, Alkon D. PKC Deficits in Alzheimer’s Disease Brains and Skin Fibroblasts. Journal of Alzheimer’s Disease. 2015;43:491-509.
  8. Khan T, Alkon D. Peripheral Biomarkers of Alzheimer’s Disease. Journal of Alzheimer’s Disease. 2015;44:729-44.